Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2026-03-02

FDA Approved: IMODIUM MULTI-SYMPTOM RELIEF — Supplemental Application (Kenvue Brands LLC)

View source ↗

Summary

The FDA approved a supplemental application to expand the labeling for Imodium Multi-Symptom Relief, a combination product of loperamide hydrochloride and dimet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • IMODIUM MULTI-SYMPTOM RELIEF (LOPERAMIDE HYDROCHLORIDE AND DIMETHICONE)

Snippet

SUPPL AP for IMODIUM MULTI-SYMPTOM RELIEF (LOPERAMIDE HYDROCHLORIDE AND DIMETHICONE)